Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00684021 · ClinicalTrials.gov registry record · Phase 2
Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)
A Phase 2 study of Left Ventricular Dysfunction, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 5
- Study locations
NCT00684021 is a Phase 2 study of Left Ventricular Dysfunction that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 120 participants, below the 1,221-participant average among 7 other Left Ventricular Dysfunction trials with a reported enrollment target (90% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT00684021, a Phase 2 study of Left Ventricular Dysfunction, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 5
- Study locations
Study Summary
Heart attacks are a leading cause of death for both men and women in the United States. A heart attack occurs when blood flow to the heart is restricted, commonly due to a blood clot that has formed in one of the coronary arteries. If the clot becomes large enough, blood flow to the heart can be blocked almost completely and the heart muscle in that area can suffer permanent injury or death. Although a percutaneous coronary intervention (PCI) can be used to open up the blocked artery and restore blood flow to the heart muscle, there may be a significant amount of heart tissue that has been irreversibly damaged. Recent studies have shown that adult stem cells from bone marrow may be able to improve heart function after a heart attack. This study will evaluate the safety and effectiveness of using adult stem cells for improving heart function in people who have had a recent heart attack and a PCI.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Adult stem cells
Study Locations (5)
Florida
- University of Florida-Department of Medicine - Gainesville
Minnesota
- Minneapolis Heart Institute Foundation - Minneapolis
Ohio
- Cleveland Clinic - Cleveland
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- Texas Heart Institute - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2008-07 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00684021
The ClinicalTrials.gov registry entry for NCT00684021 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,221-participant average among 7 other Left Ventricular Dysfunction trials with a reported enrollment target (90% lower). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Left Ventricular Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00684021 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Florida, Minnesota, Ohio.
Frequently Asked Questions
What is clinical trial NCT00684021 about?
NCT00684021 is a clinical study titled "Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)". Heart attacks are a leading cause of death for both men and women in the United States. A heart attack occurs when blood flow to the heart is restricted, commonly due to a blood clot that has formed in one of the coronary arteries. If the clot becomes large enough, blood flow to the heart can be blo...
What is the current status of trial NCT00684021?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2008-07. Estimated completion is 2012-11.
What conditions does trial NCT00684021 study?
This clinical trial studies the following conditions: Left Ventricular Dysfunction.
What interventions are being tested in trial NCT00684021?
The interventions under investigation include: Placebo (BIOLOGICAL), Adult stem cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00684021?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00684021 being conducted?
This trial has 5 study locations across Florida, Minnesota, Ohio, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Left Ventricular Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The JenaValve ALIGN-AR LVAD Registry
RECRUITING · NA
-
Sodium Lowering Vascular Effects Trial
RECRUITING · NA
-
Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
RECRUITING
-
IMpella-Protected cArdiaC Surgery Trial (IMPACT)
ACTIVE NOT RECRUITING · NA
-
PRE-DETERMINE Cohort Study
ACTIVE NOT RECRUITING
-
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.